Why bioprinting in regenerative medicine should adopt a rational technology readiness assessment
Trends in Biotechnology · 2024
DOI: 10.1016/j.tibtech.2024.03.006 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Trends in Biotechnology, 2024. Verfasst von Cathal D O'Connell und 2 weiteren Autor:innen. Beteiligte Einrichtung: Discipline of Electrical & Biomedical Engineering, RMIT University, Melbourne, VIC, Australia; Department of Surgery, St Vincent's Hospital, Universi…. Hauptthemen laut MEDLINE: Regenerative Medicine, Bioprinting, Tissue Engineering. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: Australian Research Council.
Abstract (Originalsprache)
Bioprinting is an annex of additive manufacturing, as defined by the American Society for Testing and Materials (ASTM) and International Organization for Standardization (ISO) standards, characterized by the automated deposition of living cells and biomaterials. The tissue engineering and regenerative medicine (TE&RM) community has eagerly adopted bioprinting, while review articles regularly herald its imminent translation to the clinic as functional tissues and organs. Here we argue that such proclamations are premature and counterproductive; they place emphasis on technological progress while typically ignoring the critical stage-gates that must be passed through to bring a technology to market. We suggest the technology readiness level (TRL) scale as a valuable metric for gauging the relative maturity of a bioprinting technology in relation to how it has passed a series of key milestones. We suggest guidelines for a bioprinting-oriented scale and use this to discuss the state-of-the-art of bioprinting in regenerative medicine (BRM) today. Finally, we make corresponding recommendations for improvements to BRM research that would support its progression to clinical translation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Discipline of Electrical & Biomedical Engineering, RMIT University, Melbourne, VIC, Australia; Department of Surgery, St Vincent's Hospital, University of Melbourne, Fitzroy, VIC, Australia; Aikenhead Centre for Medical…
- Phil and Penny Knight Campus for Accelerating Scientific Impact, University of Oregon, Eugene, OR, USA.
- Max Planck Queensland Centre on the Materials Science for Extracellular Matrices, Queensland University of Technology, Kelvin Grove, QLD, Australia; Centre for Behavioural Economics, Society & Technology (BEST), Queensl…
Förderung
- Australian Research Council
Zitieren
APA
O'Connell, C. D., Dalton, P. D., & Hutmacher, D. W. (2024). Why bioprinting in regenerative medicine should adopt a rational technology readiness assessment. Trends in Biotechnology. https://doi.org/10.1016/j.tibtech.2024.03.006
Vancouver
O'Connell CD, Dalton PD, Hutmacher DW. Why bioprinting in regenerative medicine should adopt a rational technology readiness assessment. Trends in Biotechnology. 2024. doi:10.1016/j.tibtech.2024.03.006
BibTeX
@article{OConnell2024,
author = {O'Connell, Cathal D and Dalton, Paul D and Hutmacher, Dietmar W},
title = {Why bioprinting in regenerative medicine should adopt a rational technology readiness assessment},
journal = {Trends in Biotechnology},
year = {2024},
doi = {10.1016/j.tibtech.2024.03.006}
}
EUVIMED